XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Dec. 31, 2011
Jun. 30, 2006
Janssen Pharmaceutica, N.V.
Y
Mar. 31, 2012
Janssen Pharmaceutica, N.V.
Mar. 31, 2011
Janssen Pharmaceutica, N.V.
Dec. 31, 2006
Janssen Pharmaceutica, N.V.
Mar. 31, 2012
Mitsubishi Tanabe Pharma Corporation
Mar. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Sep. 30, 2009
Mitsubishi Tanabe Pharma Corporation
D
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Y
payments
Mar. 31, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Mar. 31, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Alios BioPharma, Inc
D
Y
analogues
lines
Mar. 31, 2012
Alios BioPharma, Inc
Dec. 31, 2011
Alios BioPharma, Inc
Collaborative Arrangements                                    
Research and development expense associated with collaborative programs $ 37,000,000 $ 25,000,000                                
Schedule of Collaborative Arrangements                                    
Drug development costs to be paid by collaborator (as a percent)         50.00%   50.00%                      
Tiered royalty average range, as a percentage of net sales in the Janssen territories             mid-20% range                      
Up-front license payment             165,000,000                      
Deferred revenue remaining related to up-front license payment         52,800,000     3,200,000                    
Total contingent milestone payments earned         350,000,000                          
Milestone payment earned pursuant to the collaborative agreement           50,000,000                        
Notice period required to terminate without cause (in years)       1                            
License fee paid upon amendment of agreement                   105,000,000                
Notice period required to terminate without cause (in days)                   60                
Collaborative revenues recognized                                    
Royalty revenues 38,981,000 6,061,000     32,884,000                          
Collaborative revenues                                    
Amortized portion of up-front payment         3,107,000 3,107,000   9,558,000 9,558,000                  
Milestone revenues           50,000,000   485,000 1,212,000               35,000,000 35,000,000
Net payment for telaprevir development costs         (1,139,000) (1,145,000)                        
Payments for manufacturing services         4,449,000 4,154,000   3,991,000 715,000                  
Total collaborative revenues attributable to the collaboration 24,381,000 67,601,000     6,417,000 56,116,000   14,034,000 11,485,000       3,900,000 0        
Total revenues 438,737,000 73,662,000     39,301,000 56,116,000                        
Collaborative funding                       75,000,000            
Number of years over which funding will be made (in years)                       5            
Milestone payment received                     65,000,000       1,500,000      
Collaborative revenues 24,381,000 67,601,000     6,417,000 56,116,000   14,034,000 11,485,000       3,900,000 0        
Number of commercial milestone payments for achievement of certain sales levels for potentiator compound such as KALYDECO (in payments)                       2            
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                       2            
Number of nucleotide analogues discovered by acquiree (in analogues)                               2    
Research and development milestone payments, maximum                               715,000,000    
Research and development expenses 196,371,000 158,612,000                                
Commercial milestone payments, maximum                               750,000,000    
Notice period for termination of contract due to technical failure (in days)                               30    
Notice period for termination of contract after completion of clinical trials (in days)                               60    
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                               10    
Up-front payment                                   60,000,000
Deferred tax liability 241,426,000 [1]   243,707,000 [1]                           113,840,000 116,121,000
Noncontrolling Interest (Alios)                                    
Number of lines on balance sheet where noncontrolling interest is reported                               2    
Milestone Revenues           50,000,000   485,000 1,212,000               35,000,000 35,000,000
Loss before provision for income taxes                                 (5,024,000)  
Benefit from income taxes (32,000)                               2,280,000  
Change in fair value of contingent milestone and royalty payments                                 (970,000)  
Net loss attributable to noncontrolling interest (Alios) (3,714,000)                               (3,714,000)  
Restricted cash and cash equivalents (Alios) 58,017,000 [1]   51,878,000 [1]                           58,017,000 51,878,000
Prepaid expenses and other current assets 35,407,000 [1]   14,889,000 [1]                           2,318,000 2,299,000
Property and equipment, net 170,331,000 [1]   133,176,000 [1]                           1,903,000 1,925,000
Intangible assets 663,500,000 [1]   663,500,000 [1]                           250,600,000 250,600,000
Goodwill 30,992,000 [1]   30,992,000 [1]                           4,890,000 4,890,000
Other assets 10,816,000 [1]   11,268,000 [1]                           145,000 133,000
Accounts payable 73,226,000 [1]   74,642,000 [1]                           1,739,000 4,132,000
Accrued expenses and other current liabilities 241,483,000 [1]   252,299,000 [1]                           4,168,000 4,291,000
Accrued interest 6,713,000 [1]   3,363,000 [1]                           13,000 13,000
Income taxes payable (Alios) 201,000 [1]   12,075,000 [1]                           201,000 12,075,000
Deferred tax liability 241,426,000 [1]   243,707,000 [1]                           113,840,000 116,121,000
Other liabilities 10,885,000 [1]   7,287,000 [1]                           955,000 1,030,000
Redeemable noncontrolling interest (Alios) 37,496,000 [1]   37,036,000 [1]                           37,496,000 37,036,000
Noncontrolling interest (Alios) $ 137,583,000 [1]   $ 141,633,000 [1]                           $ 137,583,000 $ 141,633,000
[1] Amounts include the assets and liabilities of Vertex's variable interest entity ("VIE"), Alios BioPharma, Inc. ("Alios"). Vertex's interests and obligations with respect to the VIE's assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.